|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tanaka F and Yoneda K: Adjuvant therapy
following surgery in non-small cell lung cancer (NSCLC). Surg
Today. 46:25–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chevalier TL and Sori JC: Status and
trends of chemotherapy for advanced NSCLC. Eur J Cancer Suppl.
2:26–33. 2004. View Article : Google Scholar
|
|
4
|
Giaccone G: Clinical perspectives on
platinum resistance. Drugs. 59 (Suppl 4):S9–S17, S37-S38. 2000.
View Article : Google Scholar
|
|
5
|
Martin-Kleiner I: BORIS in human cancers-a
review. Eur J Cancer. 48:929–935. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dougherty CJ, Ichim TE, Liu L, Reznik G,
Min W, Ghochikyan A, Agadjanyan MG and Reznik BN: Selective
apoptosis of breast cancer cells by siRNA targeting of BORIS.
Biochem Biophys Res Commun. 370:109–112. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Asano T, Hirohashi Y, Torigoe T, Mariya T,
Horibe R, Kuroda T, Tabuchi Y, Saijo H, Yasuda K, Mizuuchi M, et
al: Brother of the regulator of the imprinted site (BORIS) variant
subfamily 6 is involved in cervical cancer stemness and can be a
target of immunotherapy. Oncotarget. 7:11223–11237. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Fang M, Song Y, Ren J, Fang J and
Wang X: Brother of regulator of imprinted sites (BORIS) suppresses
apoptosis in colorectal cancer. Sci Rep. 7:407862017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Longley DB, Harkin DP and Johnston PG:
5-Fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lewin F, Ringborg U, Skog S and Tribukait
B: The effect of 5-fluorouracil on cisplatin induced DNA
interstrand cross-linking in a mouse ascites tumor growing in vivo.
Anticancer Drugs. 6:465–470. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoon SL, Roh YG, Chu IS, Heo J, Kim SI,
Chang H, Kang TH, Chung JW, Koh SS, Larionov V and Leem SH: A
polymorphic minisatellite region of BORIS regulates gene expression
and its rare variants correlate with lung cancer susceptibility.
Exp Mol Med. 48:e2462016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Almeida GM, Duarte TL, Farmer PB, Steward
WP and Jones GD: Multiple end-point analysis reveals cisplatin
damage tolerance to be a chemoresistance mechanism in a NSCLC
model: Implications for predictive testing. Int J Cancer.
122:1810–1819. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen D, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosell R, Lord RVN, Taron M and Reguart N:
DNA repair and cisplatin resistance in non-small-cell lung cancer.
Lung Cancer. 38:217–227. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cohen SM and Lippard SJ: Cisplatin: From
DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol.
67:93–130. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lippard SJ: Platinum, Gold, and Other
Metal Chemotherapeutic Agents. Chemistry and Biochemistry. 209.
American Chemical Society; 1983
|
|
18
|
Basu A and Krishnamurthy S: Cellular
responses to cisplatin-induced DNA damage. J Nucleic Acids.
2010:2013672010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gomyo Y, Sasaki JI, Branch CD, Roth JA and
Mukhopadhyay T: 5-aza-2′-deoxycytidine upregulates caspase-9
expression cooperating with p53-induced apoptosis in human lung
cancer cells. Oncogene. 23:6779–6787. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bunz F, Dutriaux A, Lengauer C, Waldman T,
Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B:
Requirement for p53 and p21 to sustain G2 arrest after DNA damage.
Science. 282:1497–1501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Waldman T, Kinzler KW and Vogelstein B:
p21 is necessary for the p53-mediated G1 arrest in human cancer
cells. Cancer Res. 55:5187–1590. 1995.PubMed/NCBI
|
|
23
|
el-Deiry WS, Tokino T, Velculescu VE, Levy
DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and
Vogelstein B: WAF1, a potential mediator of p53 tumor suppression.
Cell. 75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mah L, Elosta A and Karagiannis TC:
GammaH2AX: A sensitive molecular marker of DNA damage and repair.
Leukemia. 24:679–686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chee JL, Saidin S, Lane DP, Leong SM, Noll
JE, Neilsen PM, Phua YT, Gabra H and Lim TM: Wild-type and mutant
p53 mediate cisplatin resistance through interaction and inhibition
of active caspase-9. Cell Cycle. 12:278–88. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nguyen P, Barsela G, Sun L, Bisht KS, Cui
H, Kohn EC, Feinberg AP and Gius D: BAT3 and SET1A form a complex
with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene
expression. Mol Cell Biol. 28:6720–6729. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Debruyne DN, Dries R, Sengupta S, Seruggia
D, Gao Y, Sharma B, Huang H, Moreau L, McLane M, Day DS, et al:
BORIS promotes chromatin regulatory interactions in
treatment-resistant cancer cells. Nature. 572:676–680. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kobayashi S, Boggon TJ, Dayaram T, Janne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin Y, Wang X and Jin H: EGFR-TKI
resistance in NSCLC patients: Mechanisms and strategies. Am J
Cancer Res. 4:411–435. 2014.PubMed/NCBI
|
|
30
|
Sleutels F, Soochit W, Bartkuhn M, Heath
H, Dienstbach S, Bergmaier P, Franke V, Rosa-Garrido M, van de
Nobelen S, Caesar L, et al: The male germ cell gene regulator CTCFL
is functionally different from CTCF and binds CTCF-like consensus
sites in a nucleosome composition-dependent manner. Epigenetics
Chromatin. 5:82012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Loukinov DI, Pugacheva E, Vatolin S, Pack
SD, Moon H, Chernukhin I, Mannan P, Larsson E, Kanduri C, Vostrov
AA, et al: BORIS, a novel male germ-line-specific protein
associated with epigenetic reprogramming events, shares the same
11-zinc-finger domain with CTCF, the insulator protein involved in
reading imprinting marks in the soma. Proc Natl Acad Sci USA.
99:6806–6811. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pugacheva EM, Teplyakov E, Wu Q, Li J,
Chen C, Meng C, Liu J, Robinson S, Loukinov D, Boukaba A, et al:
The cancer-associated CTCFL/BORIS protein targets multiple classes
of genomic repeats, with a distinct binding and functional
preference for humanoid-specific SVA transposable elements.
Epigenetics Chromatin. 9:352016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bergmaier P, Weth O, Dienstbach S,
Boettger T, Galjart N, Mernberger M, Bartkuhn M and Renkawitz R:
Choice of binding sites for CTCFL compared to CTCF is driven by
chromatin and by sequence preference. Nucleic Acids Res.
46:7097–7107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pugacheva EM, Rivero-Hinojosa S, Espinoza
CA, Méndez-Catalá CF, Kang S, Suzuki T, Kosaka-Suzuki N, Robinson
S, Nagarajan V, Ye Z, et al: Comparative analyses of CTCF and BORIS
occupancies uncover two distinct classes of CTCF binding genomic
regions. Genome Biol. 16:1612015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lobanenkov VV and Zentner GE: Discovering
a binary CTCF code with a little help from BORIS. Nucleus. 9:33–41.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hong JA, Kang Y, Abdullaev Z, Flanagan PT,
Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger
JI, et al: Reciprocal binding of CTCF and BORIS to the NY-ESO-1
promoter coincides with derepression of this cancer-testis gene in
lung cancer cells. Cancer Res. 65:7763–7774. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jelinic P, Stehle JC and Shaw P: The
testis-specific factor CTCFL cooperates with the protein
methyltransferase PRMT7 in H19 imprinting control region
methylation. PLoS Biol. 4:e3552006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun L, Huang L, Nguyen P, Bisht KS,
Bar-Sela G, Ho AS, Bradbury CM, Yu W, Cui H, Lee S, et al: DNA
methyltransferase 1 and 3B activate BAG-1 expression via
recruitment of CTCFL/BORIS and modulation of promoter histone
methylation. Cancer Res. 68:2726–2735. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gautam A, Li ZR and Bepler G: RRM1-induced
metastasis suppression through PTEN-regulated pathways. Oncogene.
22:2135–1242. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: The role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
